MedTrace Logo

Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)

NCT01266837 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2017-11-14

No results posted yet for this study

Summary

A single arm, open-label, multi-center phase IV clinical trial for patients with metastatic renal cell carcinoma, who have progressed on or after the first VEGF-targeted therapy.

Conditions

  • Metastatic Renal Cell Carcinoma
  • Failure of Exactly One Prior VEGF-targeted Therapy

Interventions

DRUG

Everolimus

10 mg p.o once daily

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Michael Staehler, Dr. med · Ludwig-Maximilians-University Munich, Hospital Grosshadern

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2017-09-26
Completion
2017-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01266837 on ClinicalTrials.gov